Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) PT at $10.20

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.20.

Several analysts recently issued reports on PALI shares. HC Wainwright started coverage on shares of Palisade Bio in a report on Thursday, March 26th. They set a “buy” rating and a $7.00 price objective for the company. Piper Sandler assumed coverage on shares of Palisade Bio in a research note on Monday, December 29th. They set an “overweight” rating and a $25.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. Stifel Nicolaus assumed coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price for the company. Finally, Wolfe Research assumed coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price for the company.

Palisade Bio Stock Up 9.3%

PALI stock opened at $1.99 on Friday. The company has a market capitalization of $330.10 million, a price-to-earnings ratio of -0.94 and a beta of 1.36. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64. The firm has a 50 day moving average of $1.82 and a two-hundred day moving average of $1.86.

Hedge Funds Weigh In On Palisade Bio

Several large investors have recently bought and sold shares of PALI. Cetera Investment Advisers acquired a new position in shares of Palisade Bio in the 4th quarter valued at $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio during the 4th quarter worth about $28,000. Atom Investors LP bought a new position in shares of Palisade Bio during the 4th quarter worth about $33,000. Finally, Barclays PLC bought a new position in shares of Palisade Bio during the 4th quarter worth about $35,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.